Myc Cancer Research Results

Myc, v-myc avian myelocytomatosis viral oncogene homolog: Click to Expand ⟱
Source: TCGA
Type:
Myc is a family of regulator genes and proteins that play a crucial role in cell cycle progression, apoptosis, and cellular transformation.
Myc is often found to be overexpressed or dysregulated in many types of tumors. This overexpression can lead to uncontrolled cell division and growth, contributing to the development and progression of cancer.
Myc is frequently overexpressed in various cancers, including hematological malignancies (like Burkitt lymphoma) and solid tumors (such as breast, lung, and colon cancers). This overexpression can result from genetic alterations, such as chromosomal translocations, amplifications, or mutations.

MYC is use as a clinical biomarker for risk biology-aggressiveness.
Scientific Papers found: Click to Expand⟱
6466- 1,8-Cin,    Transcriptome Analysis Reveals the Anti-Tumor Mechanism of Eucalyptol Treatment on Neuroblastoma Cell Line SH-SY5Y
- in-vitro, neuroblastoma, SH-SY5Y
AntiTum↑, TumCCA↑, PDGFRB↓, Myc↓, LEF1↓, BAD↑, APC↑, TBX3↑,
558- ART/DHA,    Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer
- Review, NA, NA
ROS↑, oncosis↑, Apoptosis↑, LysoPr↑, TumAuto↑, Wnt/(β-catenin)↑, AMP↓, NF-kB↓, Myc↓, CREBBP↓, mTOR↓, E-cadherin↑,
5634- BCA,    Molecular Mechanisms of Biochanin A in AML Cells: Apoptosis Induction and Pathway-Specific Regulation in U937 and THP-1
- in-vitro, AML, U937 - in-vitro, AML, THP1
Apoptosis↑, Casp7↑, PARP1↑, Bcl-2↓, Myc↓, CHOP↑, P21↑, p62↑, TumCCA↑, TXNIP↑, ROS↑, *antiOx↑, *Inflam↓, *neuroP↑, AntiCan↑, TumCP↓, angioG↓, TumMeta↓, VEGF↓, MMPs↓, tumCV↓, DNAdam↑, CHOP↑, cMyc↓, BioAv↓, Half-Life↓, BioAv↑,
446- CUR,    The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A Possible Mechanism Underlying the Anti-Growth and Anti-Migration in Chemoresistant Colorectal Cancer Cells
- in-vitro, CRC, SW480
IR↓, IGF-1↓, Myc↓, TumCMig↓, TumCP↓,
1443- Deg,    Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-435 - in-vitro, BC, BT549
EGFR↓, Akt↓, p‑ERK↓, NF-kB↓, p‑STAT3↓, survivin↓, Myc↓, TumCG↓, cMET↓,
6703- DFC,    Molecular docking of anti-inflammatory drug diclofenac with metabolic targets: Potential applications in cancer therapeutics.
- Analysis, Var, NA
*Inflam?, *COX1↓, *COX2↓, GLUT1↓, MCT4↓, LDHA↓, ABCG2↓, MDM2↓, MRP1/ABCC1↓, SOD2↓, Myc↓, β-catenin/ZEB1↓, VEGF↓, IKKα↓, cJun↓, E2Fs↓,
6705- DFC,    Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases
- Review, Var, NA
*Inflam↓, *Pain↓, *COX1↓, *COX2↓, *toxicity↝, *BioAv↑, *AntiAg↑, *neuroP↑, ROS↑, p73↑, Myc↓, lactateProd↓, TumCCA↑, PI3K↓, Akt↓, NF-kB↓, SOD2↓, *neuroP↑,
6688- DFC,    New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells
- in-vivo, lymphoma, U937
AntiCan↑, COX2↓, Myc↓, GLUT1↓, LDHA↓, MCT1↓, GlucoseCon↓, lactateProd↓, TumCP↓, other∅, toxicity↝,
6693- DFC,    New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells
- vitro+vivo, Var, NA
Myc↓, GLUT1↓, LDHA↓, MCT1↓, GlucoseCon↓, Glycolysis↓,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
3205- EGCG,    The Role of Epigallocatechin-3-Gallate in Autophagy and Endoplasmic Reticulum Stress (ERS)-Induced Apoptosis of Human Diseas
- Review, Var, NA - Review, AD, NA
Beclin-1↑, ROS↑, Apoptosis↑, ER Stress↑, *Inflam↓, *cardioP↑, *antiOx↑, *LDL↓, *NF-kB↓, *MPO↓, *glucose↓, *ROS↓, ATG5↑, LC3B↑, MMP↑, lactateProd↓, VEGF↓, Zeb1↑, Wnt↑, IGF-1R↑, Fas↑, Bak↑, BAD↑, TP53↓, Myc↓, Casp8↓, LC3II↑, NOTCH3↓, eff↑, p‑Akt↓, PARP↑, *Cyt‑c↓, *BAX↓, *memory↑, *neuroP↑, *Ca+2?, GRP78/BiP↑, CHOP↑, ATF4↑, Casp3↑, Casp8↑, UPR↑,
2845- FIS,    Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, p38↓, *antiOx↑, *neuroP↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, DNAdam↑, MMP↓, eff↑, ROS↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, P53↑, p65↓, Myc↓, HSP70/HSPA5↓, HSP27↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycA1/CCNA1↓, P21↑, MMP2↓, MMP9↓, TumMeta↓, MMP1↓, MMP3↓, MMP7↓, MET↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↑, uPA↓, ChemoSen↑, EMT↓, Twist↓, Zeb1↓, cFos↓, cJun↓, EGF↓, angioG↓, VEGF↓, eNOS↓, *NRF2↑, HO-1↑, NRF2↓, GSTs↓, ATF4↓,
5148- GamB,    Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics
- Review, Var, NA
AntiCan↑, angioG↓, ChemoSen↑, RadioS↑, VEGF↓, MMP2↓, MMP9↓, Telomerase↓, TrxR↓, ERK↓, HSP90↓, ROS↑, SIRT1↑, survivin↓, cFLIP↓, Casp3↑, Casp8↑, Casp9↑, BAD↓, BID↓, Bcl-2↓, BAX↑, STAT3↓, hTERT/TERT↓, NF-kB↓, Myc↓, Hif1a↓, FOXD3↑, BioAv↓, BioAv↑, P53↑, eff↓, OCR↓, MMP↓, PI3K↓, Akt↓, BBB↑, TumCG↓, TumMeta↓, BioAv↑,
2929- LT,    Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention
- in-vitro, Ovarian, NA
HK2↓, Myc↓, Glycolysis↓,
5254- NCL,    The magic bullet: Niclosamide
- Review, Var, NA
Wnt↓, β-catenin/ZEB1↓, RAS↓, STAT3↓, NOTCH↓, E2Fs↓, mTOR↓, eff↑, PD-1↓, PD-L1↓, BioAv↝, toxicity↓, BioAv↑, ETC↑, NADH:NAD↓, TCA↑, Warburg↓, Diff↑, AMPK↑, P53↑, PP2A↑, HIF-1↓, KRAS↓, Myc↓, RadioS↑, ChemoSen↑, Dose↝, Dose↑,
4900- Sal,    Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications
- Review, BC, NA
CSCs↓, Apoptosis↑, TumAuto↑, necrosis↑, TumCP↓, TumCI↓, TumCMig↓, TumCG↓, TumMeta↓, eff↑, Bcl-2↓, cMyc↓, Snail↓, ALDH↓, Myc↓, AR↓, ROS↑, NF-kB↓, PTCH1↓, Smo↓, Gli1↓, GLI2↓, Wnt↓, mTOR↓, GSK‐3β↓, cycD1/CCND1↓, survivin↓, P21↑, p27↑, CHOP↑, Ca+2↑, DNAdam↑, Hif1a↓, VEGF↓, angioG↓, MMP↓, ATP↓, p‑P53↑, γH2AX↑, ChemoSen↑,
5036- SAS,    Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
xCT↓, GSH↓, OS↑, Myc↓, CDK1↓, CD44↓, eff↑, TumCG↓,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,
3427- TQ,    Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets
ROS⇅, Fas↑, DR5↑, TRAIL↑, Casp3↑, Casp8↑, Casp9↑, P53↑, mTOR↓, Bcl-2↓, BID↓, CXCR4↓, JNK↑, p38↑, MAPK↑, LC3II↑, ATG7↑, Beclin-1↑, AMPK↑, PPARγ↑, eIF2α↓, P70S6K↓, VEGF↓, ERK↓, NF-kB↓, XIAP↓, survivin↓, p65↓, DLC1↑, FOXO↑, TET2↑, CYP1B1↑, UHRF1↓, DNMT1↓, HDAC1↓, IL2↑, IL1↓, IL6↓, IL10↓, IL12↓, TNF-α↓, iNOS↓, COX2↓, 5LO↓, AP-1↓, PI3K↓, Akt↓, cMET↓, VEGFR2↓, CXCL1↓, ITGA5↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↓, Myc↓, cycD1/CCND1↓, N-cadherin↓, Snail↓, Slug↓, Vim↓, Twist↓, Zeb1↓, MMP2↓, MMP7↓, MMP9↓, JAK2↓, STAT3↓, NOTCH↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, CDK6↓, CDC2↓, CDC25↓, Mcl-1↓, E2Fs↓, p16↑, p27↑, P21↑, ChemoSen↑,

Showing Research Papers: 1 to 19 of 19

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 19

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   GSH↓, 1,   GSTs↓, 1,   HO-1↓, 1,   HO-1↑, 1,   HO-2↓, 1,   NRF2↓, 2,   ROS↑, 9,   ROS⇅, 1,   SOD2↓, 2,   TrxR↓, 1,   xCT↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 1,   CDC2↓, 1,   CDC25↓, 1,   EGF↓, 1,   ETC↑, 1,   MMP↓, 4,   MMP↑, 1,   OCR↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↑, 1,   AMP↓, 1,   AMPK↑, 3,   ATG7↑, 1,   cMyc↓, 3,   ECAR↝, 1,   GlucoseCon↓, 3,   Glycolysis↓, 3,   HK2↓, 1,   IR↓, 1,   lactateProd↓, 4,   LDHA↓, 3,   MCT4↓, 1,   NADH:NAD↓, 1,   PDK1?, 2,   PKM2↓, 1,   PPARγ↑, 1,   SIRT1↓, 1,   SIRT1↑, 1,   TCA↑, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 5,   Akt↑, 1,   p‑Akt↓, 2,   Apoptosis↑, 4,   BAD↓, 1,   BAD↑, 3,   Bak↑, 1,   BAX↑, 3,   Bax:Bcl2↑, 1,   Bcl-2↓, 6,   Bcl-xL↓, 1,   BID↓, 2,   BIM↑, 1,   Casp3↑, 6,   Casp7↑, 2,   Casp8↓, 1,   Casp8↑, 3,   Casp9↑, 4,   cFLIP↓, 1,   Cyt‑c↑, 2,   Diablo↑, 2,   DR5↑, 1,   Fas↑, 2,   hTERT/TERT↓, 1,   iNOS↓, 2,   JNK↑, 1,   MAPK↑, 1,   Mcl-1↓, 3,   MCT1↓, 2,   MDM2↓, 2,   Myc↓, 19,   necrosis↑, 1,   NOXA↑, 1,   oncosis↑, 1,   p27↑, 2,   p38↓, 1,   p38↑, 1,   PUMA↑, 1,   RIP1↑, 1,   survivin↓, 5,   Telomerase↓, 2,   TRAIL↑, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

FOXD3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 2,   other∅, 1,   tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP↑, 4,   eIF2α↓, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,   HSP27↓, 1,   HSP70/HSPA5↓, 1,   HSP90↓, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1↑, 2,   LC3B↑, 1,   LC3II↑, 2,   p62↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

CYP1B1↑, 1,   DFF45↓, 1,   DNAdam↓, 1,   DNAdam↑, 3,   DNMT1↓, 2,   p16↑, 1,   P53↑, 6,   p‑P53↑, 1,   p73↑, 1,   PARP↑, 1,   cl‑PARP↑, 2,   PARP1↑, 1,   SIRT6↑, 1,   TP53↓, 1,   UHRF1↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK2↓, 3,   CDK4↓, 2,   cycA1/CCNA1↓, 2,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 1,   E2Fs↓, 3,   P21↓, 1,   P21↑, 5,   p‑RB1↓, 1,   TBX3↑, 1,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CD44↓, 1,   CDK8↓, 1,   cFos↓, 1,   cMET↓, 2,   CREBBP↓, 1,   CSCs↓, 1,   Diff↑, 1,   EMT↓, 2,   ERK↓, 2,   p‑ERK↓, 2,   FOXO↑, 1,   Gli1↓, 1,   GSK‐3β↓, 2,   HDAC1↓, 1,   IGF-1↓, 1,   IGF-1R↑, 1,   mTOR↓, 6,   NOTCH↓, 3,   NOTCH3↓, 1,   P70S6K↓, 1,   PDGFRB↓, 1,   PI3K↓, 4,   PTCH1↓, 1,   PTEN↑, 2,   RAS↓, 1,   Smo↓, 1,   Src↓, 1,   STAT3↓, 4,   p‑STAT3↓, 2,   TumCG↓, 4,   Wnt↓, 4,   Wnt↑, 1,   Wnt/(β-catenin)↓, 1,   Wnt/(β-catenin)↑, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   AP-1↓, 1,   APC↑, 1,   Ca+2↑, 2,   Ca+2↝, 1,   DLC1↑, 1,   E-cadherin↑, 2,   FAK↓, 1,   p‑FAK↓, 1,   Fibronectin↓, 1,   GLI2↓, 1,   ITGA5↓, 1,   KRAS↓, 1,   LEF1↓, 1,   LysoPr↑, 1,   MET↓, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 4,   MMP3↓, 1,   MMP7↓, 3,   MMP9↓, 5,   MMPs↓, 1,   N-cadherin↓, 2,   PKCδ↓, 1,   RIP3↑, 1,   Slug↓, 1,   SMAD3↓, 1,   Snail↓, 4,   TGF-β↓, 1,   TumCI↓, 1,   TumCMig↓, 2,   TumCP↓, 5,   TumMeta↓, 4,   Twist↓, 3,   TXNIP↑, 1,   uPA↓, 2,   Vim↓, 2,   Zeb1↓, 2,   Zeb1↑, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 5,   ATF4↓, 1,   ATF4↑, 1,   EGFR↓, 3,   Endoglin↑, 1,   eNOS↓, 1,   HIF-1↓, 1,   Hif1a↓, 4,   VEGF↓, 9,   VEGFR2↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   GLUT1↓, 3,   NHE1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 1,   COX2↓, 5,   CXCL1↓, 1,   CXCR4↓, 1,   IKKα↓, 1,   IL1↓, 1,   IL10↓, 1,   IL12↓, 1,   IL2↑, 1,   IL6↓, 1,   Inflam↓, 1,   JAK↓, 1,   JAK2↓, 1,   NF-kB↓, 9,   p65↓, 2,   PD-1↓, 1,   PD-L1↓, 2,   TNF-α↓, 1,  

Protein Aggregation(tgid=19) ⓘ

PP2A↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,   CDK6↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioAv↓, 2,   BioAv↑, 4,   BioAv↝, 1,   ChemoSen↑, 5,   Dose↑, 1,   Dose↝, 2,   Dose∅, 1,   eff↓, 1,   eff↑, 7,   Half-Life↓, 1,   MDR1↓, 1,   MRP1/ABCC1↓, 1,   RadioS↑, 5,   selectivity↑, 1,   TET2↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 2,   EGFR↓, 3,   hTERT/TERT↓, 1,   IL6↓, 1,   KRAS↓, 1,   Myc↓, 19,   PD-L1↓, 2,   TP53↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   AntiTum↑, 1,   OS↑, 1,   toxicity↓, 1,   toxicity↝, 1,  
Total Targets: 270

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   MPO↓, 1,   NRF2↑, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

glucose↓, 1,   LDL↓, 1,  

Cell Death(tgid=5) ⓘ

BAX↓, 1,   Cyt‑c↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   Ca+2?, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 2,   COX2↓, 2,   Inflam?, 1,   Inflam↓, 3,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   memory↑, 1,   neuroP↑, 5,   Pain↓, 1,   toxicity↝, 1,  
Total Targets: 22

Scientific Paper Hit Count for: Myc, v-myc avian myelocytomatosis viral oncogene homolog
4 Diclofenac
1 1,8-Cineole
1 Artemisinin
1 Biochanin A
1 Curcumin
1 Deguelin
1 Ellagic acid
1 EGCG (Epigallocatechin Gallate)
1 Fisetin
1 Gambogic Acid
1 Luteolin
1 Niclosamide (Niclocide)
1 salinomycin
1 Sulfasalazine
1 Shikonin
1 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:210  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page